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We screened 735 HIV-infected patients in Switzerland 
with unexplained alanine aminotransferase elevation for 
hepatitis E virus (HEV) immunoglobulin G. Although HEV 
seroprevalence in this population is low (2.6%), HEV RNA 
can persist in patients with low CD4 cell counts. Findings 
suggest chronic HEV infection should be considered as a 
cause of persistent alanine aminotransferase elevation.
Unexplained liver enzyme elevation is frequently encountered in HIV-infected persons (1). Hepatitis 
E virus (HEV) can cause deranged liver function. Chronic 
infection with HEV has been reported in patients with 
organ transplants, treated malignancies, and HIV infection 
(2–7).
The Study
The aim of this study was to investigate the prevalence 
and role of HEV infection among participants of the Swiss 
HIV Cohort Study enrolled up to December 2008 who 
had persistent elevated alanine aminotransferase (ALT) 
levels. Patients were eligible if they fulfi lled the following 
criteria: 1) >18 years of age; 2) history of >2 consecutively 
elevated ALT values (>60 IU/L); and 3) negative for both 
hepatitis B antigen and hepatitis C virus antibody. Serum 
HEV immunoglobulin (Ig) G was detected by an enzyme 
immunoassay (EIA), the MP Diagnostics HEV ELISA 
Kit (MP Biomedicals, formerly Genelabs Diagnostics, 
Singapore). Positive samples were retested, and only those 
with a repeated positive result were considered positive. 
HEV RNA was determined in plasma by real-time PCR of a 
189-bp product located in the open reading frame 2 region. 
Strains were sequenced and compared with reference HEV 
strains (GenBank) as described earlier (8).
For all patients meeting inclusion criteria, HEV 
serology was performed on the most recently stored blood 
sample. When available, for patients with positive serologic 
test results, HEV serology and blood HEV real-time PCR 
were performed on plasma samples stored 3 months before 
the fi rst documented elevated ALT value. In these patients, 
HEV PCR was also performed on samples stored at the 
time of, and 3 months after, the fi rst elevated ALT level.
To exclude occult infection, HEV PCR analysis was 
also performed on all available samples from IgG-negative 
patients with <150 CD4 cells/mm3 at the time of initial 
ALT elevation. To characterize more fully the patients with 
positive PCR, additional serologic testing was performed 
by using EIAgen HEV IgG and EIAgen HEV IgM kits
(Adaltis Ingen, Paris, France).
Of 15,713 patients in the database, 2,000 patients had 
persistently elevated ALT values. Of these, 1,256 patients 
who were co-infected with hepatitis B virus or hepatitis C 
virus and 9 with missing data were excluded; 735 patients 
met the inclusion criteria (Table 1). IgG serologic tests 
were performed at a mean of 2.1 years after the fi rst ALT 
elevation, and results were positive for 19 patients (2.6%). 
HEV-seropositive patients were more often female (p = 
0.059) and of Asian origin (p = 0.007). In the univariate 
analysis, presence of HEV IgG was not associated with 
age, route of infection, lowest CD4 count, viral load, body 
mass index, or ALT values (Table 1). However, age- and 
gender-adjusted multivariate logistic regression analysis, 
with HEV IgG status as the outcome variable, yielded 
signifi cant odds ratios for patients with low CD4 counts 
compared with patients with higher CD4 counts. Patients 
whose lowest CD4 counts were 100–350 cells/mm3 were 
4.7 times more likely to be HEV positive compared with 
those with lowest CD4 counts <100 cells/mm3 (Table 2).
In 16 of the 19 HEV seropositive patients, additional 
samples were available a median of 6.6 months (interquartile 
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range [IQR] 4.5–6.0) before the fi rst ALT elevation. 
Seroconversion from a prior negative to a positive result 
was found in 5 of these 16 patients (31.3%). There were 
no signifi cant differences in ALT values (median, interval 
between and during high ALT periods), CD4 count, or HIV 
viral load of those who exhibited HEV seroconversion 
compared to those who did not.
Real-time PCR for HEV RNA was positive in 1 of 
the 19 HEV IgG–positive patients (genotype 3b), with 
presence of HEV RNA over a 24-month period, while 
HEV IgG remained negative for the fi rst 12 months. This 
46-year-old white man, who had sex with men (MSM) and 
received a diagnosis of HIV infection in June 2001, started 
highly active antiretroviral therapy (HAART) with a CD4 
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Table 1. Population characteristics in a study of prevalence and role of HEV infection among participants in the Swiss HIV Cohort
Study, Switzerland, 2008* 
Characteristic
No. (%) all participants, 
N = 735 
No. (%) HEV negative, 
n = 716 
No. (%) HEV positive, 
n = 19 p value 
Sex 0.0587 
 M 618 (84.1) 605 (84.5) 13 (68.4) 
 F 117 (15.9) 111 (15.5) 6 (31.6) 
Ethnic group <0.0001 
 White 607 (82.6) 594 (83.0) 14 (73.7) 
 Black 70 (9.5) 69 (9.6) 1 (5.3) 
 Hispanic 26 (3.5) 25 (3.5) 1 (5.3) 
 Asian 29 (3.9) 26 (3.6) 3 (15.8) 
 Other 3 (0.4) 2 (0.28) 1 (0.14) 
Probable route of HIV infection NS
 Heterosexual 291 (39.6) 283 (39.5) 8 (42.1) 
 MSM 411 (55.9) 400 (55.9) 11 (57.9) 
 IDU 4 (0.6) 4 (0.6) 0
 Blood 5 (0.7) 5 (0.7) 0
 Unknown/other 24 (3.2) 24 (3.4) 0
Current or past IDU NS
 Yes 14 (2.3) 14 (2.0) 0
 No 721 (99.7) 702 (98.0) 19 (100.0) 
Prison history NS
 Yes 45 (6.1) 44 (6.1) 1 (5.3) 
 No 690 (93.9) 672 (93.9) 18 (94.7) 
Alcohol consumption NS
 Yes 261 (35.5) 256 (35.8) 5 (26.3) 
 No 474 (64.5) 460 (64.2) 14 (73.7) 
BMI group, kg/m2 NS
? <25 408 (55.5) 398 (55.6) 10 (52.6) 
 25.1–30? 231 (31.4) 225 (31.4) 6 (31.6) 
 >30 96 (13.1) 93 (12.9) 3 (15.8) 
ALT peak value, IU/L NS
? <180 606 (82.4) 591 (82.5) 15 (78.95) 
 >180? 129 (17.6) 125 (17.5) 4 (21.05) 
Lowest CD4 count, cells/mm3 0.0685 
 <100 276 (37.6) 273 (38.1) 3 (15.8) 
 100–350 288 (39.2) 276 (38.6) 12 (63.2) 
 >350 171 (23.2) 167 (23.3) 4 (21.1) 
HAART history NS
 Yes 610 (83.0) 595 (75.4) 15 (78.9) 
 No 125 (17.0) 121(16.9) 4 (21.6) 
Cancer occurrence NS
 Yes 25 (3.4) 24 (3.4) 1 (5.3) 
 No 710 (96.6) 692 (94.6) 18 (94.7) 
Outcome NS 
 Dead 29 (3.9) 28 (3.9) 1 (5.3) 
 Alive 652 (88.7) 638 (89.1) 14 (73.7) 
 Lost to follow-up 54 (7.4) 50 (7.0) 4 (21.1) 
*HEV, hepatitis E virus; MSM, men who have sex with men; IDU, intravenous drug use; BMI, body mass index; ALT, alanine aminotransferase; HAART, 
highly active antiretroviral therapy; NS, not significant. 
count of 34 cells/mm3 (5%) and a normal ALT level. ALT 
level increased 1 month later, but HAART was continued 
because the patient was asymptomatic. The patient refused a 
liver biopsy. Real-time PCR for HEV RNA was performed 
between August 2001 and December 2004. HEV PCR 
became negative for the virus when the CD4 count reached 
83 cells/mm3 (17.5%), and ALT levels became normal 6 
months later, when the CD4 count exceeded 100 cells/mm3. 
Figure 1 shows the course of ALT values, CD4 counts, and 
HIV and HEV plasma viral load.
Given the prolonged viremia and late seroconversion 
(IgG) observed in patients with low CD4 counts, we 
performed real-time PCR for HEV RNA on 135 samples 
obtained from 54 HEV IgG–negative patients with low 
CD4 counts (<150 cells/mm3) at the time of initial ALT 
elevation. Real-time PCR for HEV was positive in 1 HEV 
IgG–negative patient over a 5-month period (Figure 2). 
This 59-year-old MSM started HAART in October 1996 
with a CD4 count of 140 cells/mm3. CD4 counts remained 
<250 cells/mm3 over the subsequent 12 years. Real-time 
PCR for HEV RNA was performed between March 2002 
and April 2008. HEV-positive samples (genotype 3c) 
were identifi ed between October 2005 and March 2006. 
Additional serologic analysis revealed the presence of IgM 
over a 7-month period following fi rst positive real-time 
PCR but absence of IgG seroconversion.
Conclusions
This study of participants of the Swiss HIV Cohort 
Study shows a 2.6% (19/735) seroprevalence of HEV in 
HIV-infected patients without HBV or HCV infection 
with a history of persistently elevated ALT level. We did 
not fi nd higher HEV prevalence in subgroups previously 
considered at higher risk of HEV infection such as MSM, 
injection drug users, and prisoners. The prevalence in 
Switzerland is lower than in other European countries and 
the United States (9). It is now well established that pigs 
and other animal species constitute reservoirs for HEV 
and that transmission in industrialized countries occurs 
mainly through contaminated meat. We hypothesize 
that strict regulation of animal imports in Switzerland 
(10) may reduce HEV prevalence among farm animals. 
Food preferences and possible regional factors may also 
contribute to the differences between countries and merit 
further study.
We observed anti-HEV seroconversion in 5 
patients, including one with prolonged HEV RNA (>24 
months). In this single patient, who had a very low CD4 
count, seroconversion (IgG) was delayed until immune 
reconstitution occurred. As the CD4 count exceeded 100 
cells/mm3, HEV RNA cleared, and ALT levels became 
normal (Figure 1). According to a literature search, 7 real-
time PCR documented cases of HEV have been reported 
(3,4,11–14). Of these, 5 case-patients with CD4 counts 
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Table 2. Logistic regression derived odds ratios/estimates for positive HEV serology in study of prevalence and role of HEV infection
among participants in the Swiss HIV Cohort Study, Switzerland, 2008* 
Variable Odds ratio (95% CI) p value 
Male vs. female 0.207 (0.041–1.016) 0.0523 
CD4 100–350 vs. CD4 <100 per mm3 4.683 (1.268–17.295) 0.0206 
CD4 >350 vs. CD4 <100 per mm3 2.448 (0.522–11.468) 0.256 
Other ethnicity vs. Asian ethnicity 0.295 (0.073–1.191) 0.0864 
Alcohol history, no vs. yes 1.802 (0.582–5.581) 0.3071 
Risk group, other vs. MSM 0.422 (0.100–1.774) 0.2392 
Age at ALT elevation 1.017 (0.966–1.070) 0.5257 
Duration of ALT elevation 1.001 (1.000–1.002) 0.0207 
*HEV, hepatitis E virus; MSM, men who have sex with men; ALT, alanine aminotransferase. 
Figure 1. Longitudinal description of 
blood hepatitis E virus (HEV) serology, 
HEV RNA, alanine aminotransferase 
(ALT) levels, HIV RNA, and CD4 count 
in patient with chronic HEV infection, 
positive results by real-time PCR for 
HEV RNA, and seroconversion to 
immunoglobulin (Ig) G. HAART, highly 
active antiretroviral therapy.
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>200 cells/mm3 sought treatment with acute infection and 
the virus cleared, whereas in 2 patients with <200 CD4 
cells/mm3 persistent hepatitis developed (as we observed 
in our patient).
This study faced 2 common limitations regarding 
HEV diagnosis and comparability of seroprevalence: 
lack of an approved algorithm and variability of serologic 
tests in terms of sensitivity and specifi city. According to a 
recent comparative study, the test used in our study may 
underestimate seroprevalence because of its inherent lower 
sensitivity (15). Moreover, the sensitivity of EIA tests 
among immunosuppressed patients is unknown and may 
be limited. We therefore screened all HEV IgG–negative 
patients (using HEV real-time PCR) with low CD4 counts at 
the time of unexplained, elevated ALT level and identifi ed 
1 patient who had 2 positive samples over a 5-month 
period. Unfortunately, later samples were not available to 
determine the precise duration of HEV viremia.
Taken together, our results suggest that serologic 
screening alone may be insuffi cient to diagnose HEV 
infection in HIV-infected patients with very low CD4 
counts because seroconversion (IgG) may be delayed 
or not occur. When investigating unexplained, elevated 
ALT level in HIV-infected patients, we propose that HEV 
infection should be considered.
This study was fi nanced within the framework of the Swiss 
HIV Cohort Study supported by the Swiss National Science 
Foundation.
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